Antibiotic consumption and policies are of great concern in Europe, mainly due to the growing ATB resistance and failure of ATB therapy. The aim of this note is to interprete the correlation between ATB consumption and resistance to ATB in 30 European (EU) European Economic Area (EEA) countries and search for the influence of state economies (eg. GDP, health expenditures etc.) to the ATB consumption. As result of solidarity and patients behavior.
Introduction
Increasing life expectancy worldwide is a positive economic and social phenomenon in high-income countries and is caused within last 50 years by decreasing mortality on both communicable and non-communicable diseases. Vaccines and antibiotics are major factor in decreasing mortality related to infectious diseases. However, increasing ATB consumption is reported on bothhospital and nationwide levels.(1) Is ATB consumption the only driver of increased ATB resistance? Is high ATB-consumption on national level the major cause of ATB resistance or just a consequence of migration (2,3) patients behavior, education and/ or social situation? (3, 4, 5) The aim of this note is to interpret the correlation between ATB consumption and resistance to ATB in 30 European (EU) European Economic Area (EEA) countries and search for the influence of state economies (eg. GDP, health expenditures, migration, social pathology etc.) to the ATB consumption.
Methods
Data on ATB consumption and resistance were extrapolated from the ESAC study group (1) 
Results and Discussion
Consumption and resistance data from all 30 EU/EEA countries are to be found in tables 1 to 4. Out-of-pocket spending and %GDP in particular countries were compared in 4 groups according to level of consumption and resistance.
Correlation was found in 60% of countries (n=18), rest of the countries showed no correlation between consumption and resistance of ATB.
16 countries with high ATB-R (more than 20% mean ATB-R rate). 10 of them (60%) has also high ATB consumption, mainly in Southern and Eastern Europe. Romania has also the highest resistance rates (45.9%) followed by Slovakia, Greece, Bulgaria and Italy. However there were also countries in this group with low ATB-consumption and high resistance rates (Czech Republic, Hungary, Slovenia, Latvia, Lithuania, Estonia). Countries with low resistance rates, 8 of 14 countries, showed correlation with consumption and resistance, (mainly Scandinavian countries). In France, UK, Ireland and Belgium high consumption is not
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Clinical Social Work and Health Intervention Vol. 10 No. 4 2019 accompanied with high resistance rates. Explanation for this 60% consumption can be found in economy and financing of healthcare and discussed as a interesting phenomenon, which may explain this non-correlation. Countries with high resistance and consumption (group A) showed also high percentage of out of pocket spending on healthcare (28-32% vs. 13-14%). Countries with high ATB consumption but low resistance (group C) vice-versa showed significantly higher investments to healthcare (8-9% of GDP vs. 6.0-6.1% p=0.045) than in the countries with low consumption, but high ATB-R (group B). Differences are also in the spending on healthcare per capita, in group B it was on average 1400-1650USD and in group C 5500-7500USD.
Conclusions
There is a partial correlation between ATB-resistance and consumption of antibiotics in EU/EEA. 60% of European countries, which have high ATB consumption, have also high ATB-resistance and countries with low consumption tend to have low resistance rates too. However, there is also correlation between out of pocket expenditure on healthcare and high consumption of ATB and investments to healthcare per capita also correlates to low ATB-R rate, possibly due to more resources spent to hospital hygiene, surveillance and preventive programs for ATB resistance due to charges of social pathology (migration, detention, patient behavior) and social policy, of particular state (4) (5) 
